Search

everythinglearnresearchcommunity

for

Search:↓

The new drug carriers show promise for better targeting and treating ovarian cancer.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

Inhibiting ornithine decarboxylase may help prevent certain skin cancers.

Baricitinib helps treat severe hair loss in people over 65.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.

PPX causes much less hair loss than traditional taxanes.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

PRP injections did not significantly improve ovarian function in women with low ovarian reserve.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Aptamers can improve wound healing and promote hair growth.

Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.

Oophorectomy reduces ovarian cancer risk for women with BRCA mutations, finasteride lowers prostate cancer risk without raising death risk, and prophylactic mastectomy rates are rising.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.

The compound 4c showed strong potential as an anticancer agent.

Serenoa repens extract shows promise as a natural treatment for prostate cancer.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Two patients with stubborn hair loss grew hair after PDRN injections.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Baricitinib helps with early hair regrowth in people with alopecia areata.

A new gene mutation linked to Olmsted syndrome may increase cancer risk, suggesting the need for ongoing patient monitoring.

The treatment combination is effective and generally safe for lung cancer.

Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.